Compare Stocks: EXOZ, DTIL, ADAG, and PEPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.76 -0.7%	$3.48	$1.30 ▼ $4.85	$182.30M	0.54	288,008 shs	1.65 million shs
DTIL Precision BioSciences	$6.72 +4.5%	$7.21	$3.53 ▼ $9.62	$185.49M	1.27	268,953 shs	263,690 shs
EXOZ eXoZymes	$5.25 -0.4%	$6.19	$4.35 ▼ $18.40	$48.85M	3.19	8,002 shs	1,025 shs
PEPG PepGen	$2.62 +10.1%	$2.81	$1.31 ▼ $7.80	$181.46M	2.01	806,892 shs	603,693 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-3.16%	-16.62%	-29.95%	+41.18%
DTIL Precision BioSciences	0.00%	+6.50%	-7.18%	-23.29%	+17.89%
EXOZ eXoZymes	0.00%	-14.08%	-15.53%	-24.68%	-59.83%
PEPG PepGen	0.00%	+14.91%	-13.25%	+11.97%	-46.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.76 -0.7%	$3.48	$1.30 ▼ $4.85	$182.30M	0.54	288,008 shs	1.65 million shs
DTIL Precision BioSciences	$6.72 +4.5%	$7.21	$3.53 ▼ $9.62	$185.49M	1.27	268,953 shs	263,690 shs
EXOZ eXoZymes	$5.25 -0.4%	$6.19	$4.35 ▼ $18.40	$48.85M	3.19	8,002 shs	1,025 shs
PEPG PepGen	$2.62 +10.1%	$2.81	$1.31 ▼ $7.80	$181.46M	2.01	806,892 shs	603,693 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-3.16%	-16.62%	-29.95%	+41.18%
DTIL Precision BioSciences	0.00%	+6.50%	-7.18%	-23.29%	+17.89%
EXOZ eXoZymes	0.00%	-14.08%	-15.53%	-24.68%	-59.83%
PEPG PepGen	0.00%	+14.91%	-13.25%	+11.97%	-46.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.80	Moderate Buy	$8.67	214.01% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	379.91% Upside
EXOZ eXoZymes	1.50	Reduce	N/A	N/A
PEPG PepGen	2.67	Moderate Buy	$11.40	335.11% Upside

Current Analyst Ratings Breakdown

Latest EXOZ, DTIL, ADAG, and PEPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	EXOZ eXoZymes	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/10/2026	ADAG Adagene	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/28/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/26/2026	EXOZ eXoZymes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	ADAG Adagene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ADAG Adagene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$7.67M	23.77	N/A	N/A	$0.75 per share	3.68
DTIL Precision BioSciences	$34.26M	5.41	N/A	N/A	$4.03 per share	1.67
EXOZ eXoZymes	$70K	697.50	N/A	N/A	$0.40 per share	13.13
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
EXOZ eXoZymes	-$9.16M	-$1.19	N/A	N/A	N/A	N/A	-292.15%	-158.66%	N/A
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)

Latest EXOZ, DTIL, ADAG, and PEPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/2/2026	Q3 2026	DTIL Precision BioSciences	-$0.85	N/A	N/A	N/A	$1.38 million	N/A
8/13/2026	Q2 2026	EXOZ eXoZymes	N/A	-$0.33	N/A	-$0.33	N/A	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	N/A
DTIL Precision BioSciences	0.50	12.82	12.82
EXOZ eXoZymes	0.01	3.81	3.81
PEPG PepGen	N/A	13.36	13.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
DTIL Precision BioSciences	37.99%
EXOZ eXoZymes	N/A
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
DTIL Precision BioSciences	2.70%
EXOZ eXoZymes	58.00%
PEPG PepGen	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	128	66.05 million	52.05 million	Not Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	No Data
EXOZ eXoZymes	32	9.30 million	3.91 million	N/A
PEPG PepGen	57	69.26 million	68.36 million	Not Optionable

EXOZ, DTIL, ADAG, and PEPG Headlines

Recent News About These Companies

PepGen (NASDAQ:PEPG) Stock Gets Downgrade from Wall Street Zen

October 10 at 1:31 AM | americanbankingnews.com

PepGen (NASDAQ:PEPG) Stock Moved Down to Sell by Wall Street Zen

October 10 at 1:29 AM | marketbeat.com

PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts

October 5, 2026 | defenseworld.netD

PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Rating of "Moderate Buy" from Analysts

October 5, 2026 | americanbankingnews.com

PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 5, 2026 | marketbeat.com

PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC

September 18, 2026 | marketbeat.com

PepGen Inc. (PEPG) Interactive Stock Chart - Yahoo Finance

September 16, 2026 | finance.yahoo.com

DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study

August 7, 2026 | msn.com

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

August 6, 2026 | businesswire.com

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 6, 2026 | businesswire.com

PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance

July 14, 2026 | finance.yahoo.com

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

July 8, 2026 | stockhouse.com

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

10 Best NASDAQ Stocks Under $5 to Buy Right Now

May 18, 2026 | insidermonkey.com

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

May 18, 2026 | finance.yahoo.com

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

May 13, 2026 | zacks.com

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

May 7, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 30, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 28, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

April 26, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ, DTIL, ADAG, and PEPG Company Descriptions

Adagene NASDAQ:ADAG

$2.76 -0.02 (-0.72%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.76 0.00 (-0.18%)

As of 10/9/2026 07:30 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Precision BioSciences NASDAQ:DTIL

$6.72 +0.29 (+4.51%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.71 -0.01 (-0.15%)

As of 10/9/2026 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

eXoZymes NASDAQ:EXOZ

$5.33 +0.06 (+1.14%)

As of 10/9/2026 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

PepGen NASDAQ:PEPG

$2.62 +0.24 (+10.08%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.54 -0.08 (-3.17%)

As of 10/9/2026 07:30 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXOZ, DTIL, ADAG, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXOZ, DTIL, ADAG, and PEPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXOZ, DTIL, ADAG, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ, DTIL, ADAG, and PEPG Company Descriptions

Adagene NASDAQ:ADAG

Precision BioSciences NASDAQ:DTIL

eXoZymes NASDAQ:EXOZ

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXOZ, DTIL, ADAG, and PEPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXOZ, DTIL, ADAG, and PEPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXOZ, DTIL, ADAG, and PEPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ, DTIL, ADAG, and PEPG Company Descriptions

Adagene NASDAQ:ADAG

Precision BioSciences NASDAQ:DTIL

eXoZymes NASDAQ:EXOZ

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools